<DOC>
	<DOCNO>NCT02381288</DOCNO>
	<brief_summary>The purpose study evaluate effect serum testosterone ( ST ) 6 week subcutaneous ( SC ) administration different dos dose frequency TAK-448 middle-aged old men low ST level .</brief_summary>
	<brief_title>Effects TAK-448 Middle-aged Older Men With Low Testosterone</brief_title>
	<detailed_description>The drug test study call TAK-448 . TAK-448 test define dose dose frequency result clinically relevant improvement ST middle-aged old men low ST level . This study look ST level men take TAK-448 . The study enroll approximately 66 participant . Two Cohorts plan study . Cohort 1 include 3 dose group run parallel consist follow SC dos , 0.1 mcg once-daily , 0.3 mcg twice-weekly , 1.0 mcg once-weekly period 6 week . Within dose group Cohort 1 , 11 participant enrol assigned 8 receive TAK-448 3 receive placebo . Cohort 2 enrol completion Cohort 1 may include 3 dose group . The dose dosing frequency decide base result Cohort 1 . This single-center trial conduct United States . The overall time participate study 16 week . Participants make daily visit clinic 8 week , contact telephone 14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Has total ST level less 300 nanogram per deciliter ( ng/dL ) 2 separate time point Screening . 2 . Has body mass index ( BMI ) 20.0 40.0 kilogram per square meter ( kg/m^2 ) , inclusive Screening . 3 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception time sign inform consent throughout duration study 12 week last dose . 1 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disease abnormality may impact ability participant participate potentially confound study result . Participants exclude base : 1 . Has serum creatinine great ( &gt; ) 2.0 milligram per deciliter ( mg/dL ) Screening . 2 . Is receive dialysis treatment . 3 . Has American Urological Association ( AUA ) / International Prostate Symptom Score ( IPSS ) score &gt; 19 serum prostatespecific antigen ( PSA ) &gt; 4 nanogram per milliliter ( ng/mL ) Screening . 4 . Has thyrotropin ( TSH ) level less ( &lt; ) 0.3 &gt; 7.5 milliinternational unit per liter ( mIU/L ) Screening . 5 . Has systolic blood pressure &gt; 160 millimeter mercury ( mm Hg ) diastolic blood pressure &gt; 100 mm Hg ( range may repeat eligibility determination ) Screening . 6 . Has luteinizing hormone ( LH ) &gt; 9.4 unit per liter ( U/L ) Screening . 7 . Is receive insulin therapy . 8 . Has hematocrit &lt; 30 percent ( % ) &gt; 48 % Screening . 9 . Has glycosylated hemoglobin ( HbA1c ) &gt; 8.0 Screening ( Cohort 1 ) . 2 . Has type 2 diabetes mellitus define fast blood glucose &gt; 125 mg/dL , HbA1c &gt; 6.2 % , use antidiabetic medication ( Cohort 2 ) . 3 . Has clinical evidence anatomic pathological hypothalamic/pituitary/testicular disease , ( limit ) Klinefelter 's syndrome , Kallmann 's syndrome , systemic infiltrative disease ( hemochromatosis , sarcoidosis , Wilson 's disease ) , prior pituitary surgery . 4 . Has use gonadotropinreleasing hormone ( GnRH ) agonists , GnRH antagonists , antiandrogens , clomiphene , reproductive hormonerelated agent within 6 month prior Screening . 5 . Has use anabolic therapy ( testosterone , dehydroepiandrosterone [ DHEA ] , androstendione , androgen , recombinant human growth hormone ) within 1 year Screening .</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>